Sugi Predict

Sugi Predict / Compounds / SCHEMBL2776823

SCHEMBL2776823

SCHEMBL2776823

Cc1cc2c(s1)CCCC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ PABPC1 P11940 1/20 0.36
▸ MAOA P21397 4/20 0.35
▸ MAOB P27338 4/20 0.35
▸ CYP2A6 P11509 1/20 0.35
▸ PRKCI P41743 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ PNMT P11086 1/20 0.35
▸ PLK1 P53350 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ PLK3 Q9H4B4 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ BAZ2B Q9UIF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13104453 0.88 TSHR (0.42) TSHRMEN1KMT2ARAB9ACYP2C19
SCHEMBL11302021 0.76 MAOA (0.35) TSHRMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL15606074 0.76 MAOA (0.35) MEN1KMT2ARAB9ACYP2C19ALDH1A1
SCHEMBL496280 0.76 MAOA (0.39) MEN1KMT2AALDH1A1MAOAMAOB
SCHEMBL2432416 0.76 MAOA (0.35) MEN1KMT2AALDH1A1MAOAMAOB
SCHEMBL23482158 0.76 MEN1 (0.40) TSHRMEN1KMT2ARAB9ACYP2C19
SCHEMBL23462327 0.76 ALDH1A1 (0.37) MEN1KMT2AALDH1A1SMN1; SMN2MAOA
SCHEMBL8917048 0.74 MEN1 (0.46) TSHRMEN1KMT2ARAB9ACYP2C19
SCHEMBL3138935 0.72 MEN1 (0.33) TSHRMEN1KMT2ARAB9ACYP2C19
SCHEMBL2436103 0.72 DAO (0.61) MEN1KMT2ARAB9ACYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630521-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed
US-20230147360-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-11 — — US disclosed
US-20230147360-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-11 — — US disclosed
US-20230147360-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-11 — — US disclosed
WO-2021113809-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed
US-10961258-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-30 — — US disclosed
US-10961258-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-30 — — US disclosed
US-20200270273-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-08-27 — — US disclosed
US-20200270273-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-08-27 — — US disclosed
EP-3237547-B1 DIRECT DYES AND COMPOSITION COMPRISING THE DYES KAO GERMANY GMBH (DE) 2019-03-20 — — EP disclosed
EP-2230243-A1 Pharmaceutical compounds Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-22 — — EP disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed
US-7700609-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-20 — — US disclosed
EP-1692140-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-12-09 — — EP disclosed
EP-0127143-B1 NOVEL ARYLOXYCYCLOALKANOLAMINOALKYLENE ARYL KETONES MERRELL DOW PHARMACEUTICALS INC. (US) 1990-03-21 — — EP disclosed
US-4868315-A HYPOTENSIVE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1989-09-19 — — US disclosed
US-4745222-A HYPOTENSIVE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1988-05-17 — — US disclosed
US-4191830-A HERBICIDES AND ANIMAL GROWTH REGULATORS AMERICAN CYANAMID COMPANY (US) 1980-03-04 — — US disclosed
US-4156670-A UREAS AND THIOUREAS, HERBICIDES, ANIMAL GROWTH REGULATORS AMERICAN CYANAMID COMPANY (US) 1979-05-29 — — US disclosed
US-4036979-A ANIMAL GROWTH RATE ACCELERATOR AMERICAN CYANAMID COMPANY (US) 1977-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147360-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA TSHR 2786/4885MEN1 4477/4885KMT2A 2884/4885
US-10961258-B2 Heterocyclic amides as kinase inhibitors CNKSR1, ARAF, BRAF TSHR 661/4885MEN1 2734/4885KMT2A 353/4885
US-20200270273-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS CNKSR1, ARAF, BRAF TSHR 661/4885MEN1 2734/4885KMT2A 353/4885
US-12630521-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 TSHR 497/4885MEN1 4201/4885KMT2A 2749/4885
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS CNR2, CNR1, OPRK1 TSHR 475/4885MEN1 4799/4885KMT2A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.